Found: 96
Select item for more details and to access through your institution.
Efficacy and safety of laparoscopic hepatectomy for hepatocellular carcinoma comorbid with cirrhosis.
- Published in:
- Gastroenterology Review / Przegląd Gastroenterologiczny, 2020, v. 15, n. 3, p. 225, doi. 10.5114/pg.2020.99039
- By:
- Publication type:
- Article
C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-12058-y
- By:
- Publication type:
- Article
Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study.
- Published in:
- Infectious Diseases & Therapy, 2020, v. 9, n. 4, p. 851, doi. 10.1007/s40121-020-00329-y
- By:
- Publication type:
- Article
Cancer Cachexia: Its Mechanism and Clinical Significance.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 16, p. 8491, doi. 10.3390/ijms22168491
- By:
- Publication type:
- Article
Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 14, p. 4939, doi. 10.3390/ijms21144939
- By:
- Publication type:
- Article
HB Surface Antigen Level as a Useful Predictor for the Treatment Response to Tenofovir Alafenamide in Nucleoside Analogue Naïve Chronic Hepatitis B.
- Published in:
- In Vivo, 2023, v. 37, n. 2, p. 726, doi. 10.21873/invivo.13134
- By:
- Publication type:
- Article
Screening Tools for Sarcopenia.
- Published in:
- In Vivo, 2021, v. 35, n. 6, p. 3001, doi. 10.21873/invivo.12595
- By:
- Publication type:
- Article
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
- Published in:
- Cancer Reports, 2024, v. 7, n. 4, p. 1, doi. 10.1002/cnr2.2042
- By:
- Publication type:
- Article
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
- Published in:
- Cancer Reports, 2022, v. 5, n. 2, p. 1, doi. 10.1002/cnr2.1464
- By:
- Publication type:
- Article
Association between Administration of Antithrombotics and Intraperitoneal Hemorrhage in Patients Undergoing Percutaneous Interventions for Liver Diseases.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 11, p. 2527, doi. 10.3390/jcm10112527
- By:
- Publication type:
- Article
Sarcopenia and Frailty in Liver Cirrhosis.
- Published in:
- Life (2075-1729), 2021, v. 11, n. 5, p. 399, doi. 10.3390/life11050399
- By:
- Publication type:
- Article
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 10, p. 1361, doi. 10.1111/apt.18237
- By:
- Publication type:
- Article
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 2, p. 233, doi. 10.1111/apt.18037
- By:
- Publication type:
- Article
Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients.
- Published in:
- Mediators of Inflammation, 2015, v. 2015, p. 1, doi. 10.1155/2015/608216
- By:
- Publication type:
- Article
Can Iodixanol Prevent Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis? A Prospective, Randomized, Controlled Trial.
- Published in:
- Digestive Diseases, 2019, v. 37, n. 3, p. 255, doi. 10.1159/000496349
- By:
- Publication type:
- Article
Metabolic dysfunction‐associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis.
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 429, doi. 10.1111/hepr.13994
- By:
- Publication type:
- Article
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
- Published in:
- Hepatology Research, 2024, v. 54, n. 4, p. 382, doi. 10.1111/hepr.13991
- By:
- Publication type:
- Article
Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
- Published in:
- Hepatology Research, 2023, v. 53, n. 10, p. 1031, doi. 10.1111/hepr.13934
- By:
- Publication type:
- Article
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
- Published in:
- Hepatology Research, 2023, v. 53, n. 8, p. 737, doi. 10.1111/hepr.13905
- By:
- Publication type:
- Article
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice.
- Published in:
- Hepatology Research, 2022, v. 52, n. 9, p. 773, doi. 10.1111/hepr.13797
- By:
- Publication type:
- Article
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 5, p. 462, doi. 10.1111/hepr.13748
- By:
- Publication type:
- Article
Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 235, doi. 10.1111/hepr.13739
- By:
- Publication type:
- Article
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 3, p. 308, doi. 10.1111/hepr.13734
- By:
- Publication type:
- Article
Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
- Published in:
- Hepatology Research, 2021, v. 51, n. 8, p. 880, doi. 10.1111/hepr.13644
- By:
- Publication type:
- Article
Sequential therapy involving an early switch from entecavir to pegylated interferon‐α in Japanese patients with chronic hepatitis B.
- Published in:
- Hepatology Research, 2018, v. 48, n. 6, p. 459, doi. 10.1111/hepr.13050
- By:
- Publication type:
- Article
Two healthy females with fulminant hepatic failure caused by herpes simplex virus infection.
- Published in:
- Pathology International, 2014, v. 64, n. 1, p. 48, doi. 10.1111/pin.12128
- By:
- Publication type:
- Article
Volumetric and Functional Regeneration of Remnant Liver With Massive Ascites After Hepatectomy.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Grip Strength in Patients with Gastrointestinal Diseases.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 8, p. 2079, doi. 10.3390/jcm11082079
- By:
- Publication type:
- Article
The Relevance in the Neutrophil to Lymphocyte Ratio and the SARC-F Score in Gastrointestinal Diseases.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 7, p. 2012, doi. 10.3390/jcm11072012
- By:
- Publication type:
- Article
The Relationship between the SARC-F Score and the Controlling Nutritional Status Score in Gastrointestinal Diseases.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 3, p. 582, doi. 10.3390/jcm11030582
- By:
- Publication type:
- Article
Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 18, p. 4214, doi. 10.3390/jcm10184214
- By:
- Publication type:
- Article
Comparison of SARC-F Score among Gastrointestinal Diseases.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 18, p. 4099, doi. 10.3390/jcm10184099
- By:
- Publication type:
- Article
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
- Published in:
- Cancers, 2023, v. 15, n. 17, p. 4348, doi. 10.3390/cancers15174348
- By:
- Publication type:
- Article
Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers.
- Published in:
- Cancers, 2022, v. 14, n. 1, p. 10, doi. 10.3390/cancers14010010
- By:
- Publication type:
- Article
Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression.
- Published in:
- Cancers, 2020, v. 12, n. 8, p. 2286, doi. 10.3390/cancers12082286
- By:
- Publication type:
- Article
Dysbiosis and liver diseases (Review).
- Published in:
- International Journal of Molecular Medicine, 2021, v. 48, n. 3, p. N.PAG, doi. 10.3892/ijmm.2021.5016
- By:
- Publication type:
- Article
Pathophysiology and mechanisms of primary sarcopenia (Review).
- Published in:
- International Journal of Molecular Medicine, 2021, v. 48, n. 2, p. N.PAG, doi. 10.3892/ijmm.2021.4989
- By:
- Publication type:
- Article
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma.
- Published in:
- Liver International, 2024, v. 44, n. 1, p. 113, doi. 10.1111/liv.15753
- By:
- Publication type:
- Article
Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
- Published in:
- Liver International, 2020, v. 40, n. 4, p. 968, doi. 10.1111/liv.14405
- By:
- Publication type:
- Article
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 209, doi. 10.1159/000527402
- By:
- Publication type:
- Article
What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 2, p. 115, doi. 10.1159/000513355
- By:
- Publication type:
- Article
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed‐effects regression model approach.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 24, p. 21680, doi. 10.1002/cam4.6726
- By:
- Publication type:
- Article
Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 17, p. 17849, doi. 10.1002/cam4.6416
- By:
- Publication type:
- Article
Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 7, p. 7772, doi. 10.1002/cam4.5535
- By:
- Publication type:
- Article
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 6, p. 6980, doi. 10.1002/cam4.5495
- By:
- Publication type:
- Article
Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 5, p. 5293, doi. 10.1002/cam4.5337
- By:
- Publication type:
- Article
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 4, p. 4259, doi. 10.1002/cam4.5294
- By:
- Publication type:
- Article
Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 1, p. 325, doi. 10.1002/cam4.4854
- By:
- Publication type:
- Article
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 20, p. 3796, doi. 10.1002/cam4.4763
- By:
- Publication type:
- Article
Impact of first‐line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
- Published in:
- Journal of Gastroenterology & Hepatology, 2023, v. 38, n. 8, p. 1389, doi. 10.1111/jgh.16225
- By:
- Publication type:
- Article